Patients with systemic lupus erythematosus (SLE) may form clusters with clinical manifestations and autoantibodies.
Objective
The objective of this report is to study whether SLE patients with positive rheumatoid factor (RF) have a special clinical and/or serological profile.
Methods
A retrospective study of 467 SLE patients seen at a single rheumatology unit was conducted. Epidemiological data (age, gender, age at disease onset, ethnic background and tobacco use), clinical data (malar rash, photosensitivity, oral ulcers, discoid lesions, serositis, glomerulonephritis, convulsions, psychosis, hemolytic anemia, leukopenia, lymphocytopenia, arthritis and hypothyroidism) and serological profile (anti-dsDNA, anti-Ro/SS-A, anti-La/SS-B, anti-RNP, anti-Sm, IgG aCL, IgM aCL, lupus anticoagulant, direct Coombs and RF) were collected. Patients with positive and negative RF were compared.
Results
RF was found in 24.9% of the sample. In univariate analysis, RF was positively associated with butterfly rash (p = 0.04), anti-Ro (p = 0.03), anti-Sm antibodies (p = 0.01) and hypothyroidism (p = 0.01) and negatively associated with glomerulonephritis (p = 0.003). Logistic regression showed that only glomerulonephritis (p = 0.03; OR = 0.45; 95% CI = 0.21–0.93) and anti-Ro (p = 0.009; OR = 2.3; 95% CI = 1.24–4.57) were independent associations.
Conclusion
In our sample RF was associated with protection from glomerulonephritis and with higher prevalence of anti-Ro antibodies.
Artim-EsenBÇeneEŞahinkayaYet al.Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol2014; 41: 1304–1310.
2.
TangXHuangYDengWTangLWengWZhangX. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: A retrospective review of 917 patients in South China. Medicine (Baltimore)2010; 89: 62–67.
3.
GavrilăBICiofuCStoicaV. Biomarkers in rheumatoid arthritis, what is new?J Med Life2016; 9: 144–148.
4.
AletahaDAlastiFSmolenJS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis2013; 72: 875–880.
5.
TanEMSmolenJS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med2016; 213: 1937–1950.
6.
SokoloveJJohnsonDSLaheyLJet al.Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol2014; 66: 813–821.
7.
EstesDChristianCL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore)1971; 50: 85–95.
8.
WitteTHartungKSachseCet al.Rheumatoid factors in systemic lupus erythematosus: Association with clinical and laboratory parameters. SLE study group. Rheumatol Int2000; 19: 107–111.
9.
CerveraRKhamashtaMAFontJet al.Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore)1993; 72: 113–124.
10.
CorkeCE. Rheumatoid factor and renal disease in systemic lupus erythematosus. Rheumatol Rehab1987; 17: 76–78.
11.
DavisJSBolletAJ. Complement levels, rheumatoid factor and renal disease in systemic lupus erythematosus. Arthritis Rheum1966; 9: 499–505.
12.
HillGSHinglaisNTronFBachJF. Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am J Med1978; 64: 61–79.
13.
PinillosRMNolla i SoleJMJuanola i RouraXFerranzVPPalacinAVSampereIM. Rheumatoid factor in patients with systemic lupus erythematosus. Ann Rheum Dis1987; 46: 877–878.
14.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
15.
MiyakisSLockshinMDAtsumiTet al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
16.
VitaliCBomardieriSJonssonRet al.Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American European consensus group. Ann Rheum Dis2002; 61: 554–558.
17.
HelinHKorpelaMMustonenJPasternackA. Rheumatoid factor in rheumatoid arthritis associated renal disease in lupus nephritis. Ann Rheum Dis1986; 45: 508–511.
18.
KantorGLBickelYBBarnettEV. Coexistence of systemic lupus erythematosus and rheumatoid arthritis. Report of a case and review of the literature, and clinical, pathologic and serologic observations. Am J Med1969; 47: 433–444.
19.
BaldwinDSLowensteinJRothfieldNFGalloGMcCluskeyRT. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med1970; 73: 929–942.
20.
SkareTLSilvaMBHollerAPChavezPA. Protective role of rheumatoid factor in lupus nephritis. Clin Exp Rheumatol2009; 27: 895–895.
21.
ShinguMEzakiINobunagaM. Complement-activating properties of immune complexes are suppressed by IgM rheumatoid factor and enhanced by IgG rheumatoid factor. Rheumatol Int1988; 8: 95–100.
22.
BoltonWKSchrockJDavisJ. Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus. Arthritis Rheum1982; 25: 297–303.
23.
HobbsRNLeaDJPhuaKKJohnsonPM. Binding of isolated rheumatoid factors to histone proteins and basic polycations. Ann Rheum Dis1983; 42: 435–438.
24.
AgnelloVArbetterAIbañez de KasepGPowellRTanEMJoslinF. Evidence for a subset of rheumatoid factors that cross-react with DNA-histone and have a direct cross-idiotype. J Exp Med1980; 151: 1514–1527.
25.
RotherNPieterseELubbersJHilbrandsLvan der VlagJ. Acetylated histones in apoptotic microparticles drive the formation of neutrophil extracellular traps in active lupus nephritis. Front Immunol2017; 8: 1136–1136.
26.
DiekerJBerdenJHBakkerMet al.Autoantibodies against modified histone peptides in SLE patients are associated with disease activity and lupus nephritis. PLoS One2016; 11: e0165373–e0165373.
27.
IrigoyenPLeeATWenerMHet al.Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum2005; 52: 3813–3818.
28.
MorrisDLFernandoMMTaylorKEet al.MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun2014; 15: 210–217.
29.
ChienJWLinCYYangLY. Correlation between anti-Ro/La titers and clinical findings of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi (Taipei)2001; 64: 283–291.
30.
CeccarelliFMassaroLPerriconeCet al.Jaccoud’s arthropathy in systemic lupus erythematosus: Clinical, laboratory and ultrasonographic features. Clin Exp Rheumatol2017; 35: 674–677.
31.
SantiagoMBGalvãoV. Jaccoud arthropathy in systemic lupus erythematosus: Analysis of clinical characteristics and review of the literature. Medicine (Baltimore)2008; 87: 37–44.
32.
KaplanDGinzlerEMFeldmanJ. Arthritis and nephritis in patients with systemic lupus erythematosus. J Rheumatol1991; 18: 223–229.
33.
ManoussakisMNGeorgopoulouCZintzarasEet al.Sjögren’s syndrome associated with systemic lupus erythematosus: Clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum2004; 50: 882–891.
